SCHEMBL3485926

SCHEMBL3485926

CC(C)N(C1CCN(CC(=O)Nc2ccc(OC(F)(F)F)cc2)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 6/20 0.53
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
ATM Q13315 1/20 0.51
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
POLB P06746 1/20 0.47
KCNA5 P22460 1/20 0.45
UBE2M P61081 1/20 0.45
DCUN1D1 Q96GG9 1/20 0.45
EPHX2 P34913 1/20 0.45
TSHR P16473 1/20 0.45
LIPE Q05469 1/20 0.45
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485300 0.93 SMN1; SMN2 (0.52) CACNA1BKMT2AALDH1A1LMNAHSD17B10
SCHEMBL13541705 0.92 KMT2A (0.51) CACNA1BKMT2AMEN1ATMALDH1A1
SCHEMBL3485824 0.91 ALDH1A1 (0.52) CACNA1BALDH1A1LMNAHSD17B10MAPT
SCHEMBL3485918 0.90 TSHR (0.56) CACNA1BALDH1A1LMNAHSD17B10MAPT
SCHEMBL3485688 0.89 ALDH1A1 (0.50) CACNA1BKMT2AMEN1ALDH1A1LMNA
SCHEMBL3484989 0.87 RORC (0.55) CACNA1BALDH1A1LMNAHSD17B10MAPT
SCHEMBL3485705 0.86 ALDH1A1 (0.54) ALDH1A1LMNAHSD17B10MAPTSMN1; SMN2
SCHEMBL3485265 0.84 ALDH1A1 (0.47) CACNA1BALDH1A1LMNAHSD17B10MAPT
SCHEMBL3759221 0.83 ALDH1A1 (0.47) ALDH1A1LMNAHSD17B10MAPTSMN1; SMN2
SCHEMBL3486183 0.82 LMNA (0.48) CACNA1BKMT2AMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US claimed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B CACNA1B 3/4885KMT2A 2462/4885MEN1 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.